
Photo taken from Drew Moghanaki/X
Apr 4, 2024, 13:39
Drew Moghanaki: It’s reassuring to see longitudinal data aligning with the recommendations we provide patients with stage I NSCLC deciding between surgery and SBRT during usual care
Drew Moghanaki, Lung Cancer Specialist at UCLA Health Jonsson Cancer Center, shared a post on X:
“It’s reassuring to see longitudinal data aligning with the recommendations we provide patients with stage I NSCLC deciding between surgery and SBRT during usual care. As we say, ‘It’s a bumpier road in the beginning after surgery, yet patients have similar QOL a year later regardless of which upfront treatment they received.’ ”
Additional information.
Source: Drew Moghanaki/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 15:06
Feb 21, 2025, 14:27
Feb 21, 2025, 14:13
Feb 21, 2025, 13:29